FDA approves Transcept middle-of-the-night sleep drug Intermezzo

Transcept Pharmaceuticals Inc.’s middle-of-the-night sleep drug won approval Wednesday from the Food and Drug Administration.
Now it is up to Purdue Pharmaceuticals, the partner of Richmond-based Transcept (NASDAQ: TSPT), to say if it will commercialize the lozenge, called Intermezzo. Purdue has until Dec. 8 to notify Transcept of its decision.